Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

within
I am searching for a
Reset Form
placeholder image: silhouette of male physician

Bruce L. Levine, PhD Researcher

Barbara and Edward Netter Professor in Cancer Gene Therapy

Dr. Levine is employed by Penn Medicine.

No Patient Satisfaction Reviews
Why not?

There is no publicly available rating for this medical professional for one of the following reasons:

  1. He or she is not employed by Penn Medicine.
  2. He or she does not see patients in a medical practice setting.
  3. He or she sees patients but has not yet received the minimum 30 patient satisfaction reviews in the past 12 months, ensuring that the rating is statistically reliable and a true reflection of patient satisfaction.
X

Clinical Specialties

Practice Locations and Appointments

Memberships

Abstract reviewer for American Society for Gene Therapy Annual Meeting, Cell Processing and Vector Production, National Abstract reviewer for American Society for Gene Therapy Annual Meeting, Cell Processing and Vector Production, National Abstract reviewer for American Society for Gene Therapy Annual Meeting, National Abstract reviewer for International Society for Cellular Therapy Annual Meeting, Gene Therapy, International Abstract reviewer for International Society for Cellular Therapy Annual Meeting, Gene Therapy, International Abstract reviewer for International Society for Cellular Therapy Annual Meeting, Gene Therapy, International Abstract reviewer for International Society for Cellular Therapy Annual Meeting, Gene Therapy, International Abstract reviewer for International Society for Cellular Therapy Annual Meeting, Gene Therapy, International Abstract reviewer for International Society for Cellular Therapy Annual Meeting, International American Association for the Advancement of Science, National American Society for Gene and Cell Therapy, National American Society of Gene Therapy, National Cambridge Healthtech Institute, National Cancer Prevention and Research Institute of Texas: Texas Access to Cancer Cell Therapies (TACCT), National Coordinating Abstract reviewer for American Society for Gene Therapy Annual Meeting, Cell Processing and Vector Production, National International Society for Cellular Therapy, International National Heart Lung and Blood Institute Cure Sickle Cell Initiative, National NIH Study Section, Immunology Integrated Review Group SSS-4 SBIR/STTR, National NIH/NHLBI Program: Production Assistance for Cellular Therapies, National NIH/NIAID Clinical Trial Planning (R34) Grants Study Section, National NIH/NIAID Study Section, Center for AIDS Research: D-CFAR, CFAR, National NIH/NIAID Study Section, Center for AIDS Research: D-CFAR, CFAR, National

Hospital Affiliation

Dr. Levine is employed by Penn Medicine.

Research

Description of Research Expertise:

Immunology, Cell and Gene Therapy

Selected Publications:

Cohen Adam D, Garfall Alfred L, Stadtmauer Edward A, Melenhorst J Joseph, Lacey Simon F, Lancaster Eric, Vogl Dan T, Weiss Brendan M, Dengel Karen, Nelson Annemarie, Plesa Gabriela, Chen Fang, Davis Megan M, Hwang Wei-Ting, Young Regina M, Brogdon Jennifer L, Isaacs Randi, Pruteanu-Malinici Iulian, Siegel Don L, Levine Bruce L, June Carl H, Milone Michael C: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. The Journal of Clinical Investigation 130 : 126397,2019.

Stein Andrew M, Grupp Stephan A, Levine John E, Laetsch Theodore W, Pulsipher Michael A, Boyer Michael W, August Keith J, Levine Bruce L, Tomassian Lori, Shah Sweta, Leung Mimi, Huang Pai-Hsi, Awasthi Rakesh, Mueller Karen Thudium, Wood Patricia A, June Carl H: Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells. CPT: pharmacometrics & systems pharmacology : 2019.

Harrison Richard P, Zylberberg Ezequiel, Ellison Simon, Levine Bruce L: Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods. Cytotherapy 21 (2): 224-233,2019.

Mueller Karen T, Waldron Edward R, Grupp Stephan A, Levine John E, Laetsch Theodore W, Pulsipher Michael A, Boyer Michael W, August Keith, Hamilton Jason, Awasthi Rakesh, Stein Andrew M, Sickert Denise, Chakraborty Abhijit, Levine Bruce L, June Carl H, Tomassian Lori, Shah Sweta, Leung Mimi, Taran Tetiana, Wood Patricia A, Maude Shannon L: Clinical Pharmacology of Tisagenlecleucel in B-Cell Acute Lymphoblastic Leukemia. Clinical Cancer Research 24 (24): 6175,2018.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ: Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine 24 (10): 1499-1503,2018.

Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, Melenhorst JJ, Milone MC: Reducing Ex Vivo Culture Improves the Anti-leukemic Activity of Chimeric Antigen Receptor (CAR)-T Cells Cancer Immunol Res. 6 (9): 100-1109,2018.

Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD, Landsburg DJ, Youngman MR, Levine BL, Porter DL, June CH, Schuster SJ: Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma Blood 132 (10): 1022-1026,2018.

Fraietta JA1, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, DeNizio JE, Reddy S, Hwang Y, Gohil M, Kulikovskaya I, Nazimuddin F, Gupta M, Chen F, Everett JK, Alexander KA, Lin-Shiao E, Gee MH, Liu X, Young RM, Ambrose D, Wang Y, Xu J, Jordan MS, Marcucci KT, Levine BL, Garcia KC, Zhao Y, Kalos M, Porter DL, Kohli RM, Lacey SF, Berger SL, Bushman FD, June CH, Melenhorst JJ: Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells Nature 558 (7709): 307-312,2018.

Fraietta Joseph A, Lacey Simon F, Orlando Elena J, Pruteanu-Malinici Iulian, Gohil Mercy, Lundh Stefan, Boesteanu Alina C, Wang Yan, O'Connor Roddy S, Hwang Wei-Ting, Pequignot Edward, Ambrose David E, Zhang Changfeng, Wilcox Nicholas, Bedoya Felipe, Dorfmeier Corin, Chen Fang, Tian Lifeng, Parakandi Harit, Gupta Minnal, Young Regina M, Johnson F Brad, Kulikovskaya Irina, Liu Li, Xu Jun, Kassim Sadik H, Davis Megan M, Levine Bruce L, Frey Noelle V, Siegel Donald L, Huang Alexander C, Wherry E John: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine 24 (5): 563-571,2018.

Garfall Alfred L, Stadtmauer Edward A, Hwang Wei-Ting, Lacey Simon F, Melenhorst Jan Joseph, Krevvata Maria, Carroll Martin P, Matsui William H, Wang Qiuju, Dhodapkar Madhav V, Dhodapkar Kavita, Das Rituparna, Vogl Dan T, Weiss Brendan M, Cohen Adam D, Mangan Patricia A, Ayers Emily C, Nunez-Cruz Selene, Kulikovskaya Irina, Davis Megan M, Lamontagne Anne, Dengel Karen, Kerr Naseem Ds, Young Regina M, Siegel Donald L, Levine Bruce L, Milone Michael C, Maus Marcela V, June Carl H: Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI insight 3 (8): e120505,2018.

Academic Contact Info

Center for Cellular Immunotherapies
Smilow 8-114
3400 Civic Center Boulevard

Philadelphia, PA 19104
Phone: (215) 746-1481
Patient appointments: 800-789-7366 (PENN)